Table 6 Aliskren monotherapy and renal effects in simple hypertension patients and different types of patients
Outcomes | No. of SRs | No. of original studies | No. of cases/controls | Follow-up range (weeks) | Estimate (95%CI) | P-value |
|---|---|---|---|---|---|---|
changes of sCr or eGFR | ||||||
 aliskiren vs placebo | 1 | 3 | 6812/5448 | NA | 0.97 [0.81–1.16] | 0.73 |
BUN > 40 mg / dL | ||||||
 aliskiren vs placebo | 1 | NA | 1508/753 | 8 | 1.50 [0.06–36.75] | 0.8 |
 aliskiren vs ARBs | 1 | NA | 4579/1223 | 8–52 | 1.16 [0.33–4.06] | 0.82 |
 aliskiren vs HCT | 1 | NA | 4579/1113 | 8–52 | 0.79 [0.26–2.42] | 0.68 |
Creatinine level > 2.0 mg /dL | ||||||
 aliskiren vs placebo | 1 | NA | 1508/753 | 8 | 1.50 [0.06–36.75] | 0.8 |
 aliskiren vs ARBs | 1 | NA | 4579/1223 | 8–52 | 0.71 [0.19–2.68] | 0.62 |
 aliskiren vs HCT | 1 | NA | 4579/1113 | 8–52 | 4.13 [0.24–71.59] | 0.33 |
eGFR < 30 mL /min /1.73 m2 | ||||||
 aliskiren vs ARBs | 1 | NA | 4579/1223 | 8–52 | 0.53 [0.13–2.13] | 0.37 |
 aliskiren vs HCT | 1 | NA | 4579/1113 | 8–52 | 3.16 [0.18–56.09] | 0.43 |
Hyperkalaemia | ||||||
 aliskiren vs placebo | 1 | NA | 1405/752 | 8 | 1.40 [0.51–3.87] | 0.52 |
 aliskiren vs ARBs | 1 | NA | NA | 4–8 | 0.93 [0.51–1.70] | 0.82 |
 aliskiren vs HCT | 1 | NA | 5450/1113 | NA | 0.87 [0.62–1.24] | 0.43 |